Sanofi and Cheplapharm, a Germany-based specialty pharma, intend to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm.
“Cheplapharm has been a trusted partner for more than a decade and this transaction significantly builds on its prior acquisitions from Sanofi’s mature medicines portfolio,” said Thomas Grenier, executive vice president, General Medicines, Sanofi. “This new partnership, together with our equity stake in Cheplapharm, underscores our commitment to ensuring patients continue to benefit from today’s essential medicines while also pursuing tomorrow’s breakthroughs.”
As part of the project, three manufacturing sites in Hungary, Singapore and France, would be transferred to Cheplapharm.
“We are incorporating products that complement our extensive portfolio, as well as the expertise and manufacturing capabilities required to produce a flagship product, Lovenox/Clexane,” said Edeltraud Lafer and Sebastian Braun, both co-CEOs of Cheplapharm. “This represents a long-term pharmaceutical and industrial commitment: to invest in our sites and their expertise, to preserve rare skills, and to ensure the long-term availability of these treatments for patients.”
